Adjuvant immunotherapy in bronchogenic carcinoma.
Ten patients with locally far advanced bronchogenic carcinoma were treated with autologous tumor vaccine after a radical surgical resection. Three of 10 patients treated with tumor vaccine are alive (median survival of 26 months) whereas all nine patients in the control group are dead (median survival of 6.5 months). Active immunotherapy adjunct to radical surgery appeared to improve cellular immunity of the treated patients in the postoperative period, and the migration inhibition test indicated sensitization of treated patients against their tumor.
D000951:Antigens, Neoplasm; D002283:Carcinoma, Bronchogenic / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D005500:Follow-Up Studies; D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008213:Lymphocyte Activation; D009439:Neuraminidase / Q000494:pharmacology; D009518:New York; D012882:Skin Tests
D000951:Antigens, Neoplasm; D009439:Neuraminidase